Objective: To measure patient-reported quality of life before and after botulinum toxin A treatment of post-parotidectomy Frey's syndrome (gustatory sweating).
Introduction
Dr Lucja Frey first described the syndrome of gustatory sweating in 1923, calling it 'the auriculotemporal nerve syndrome'.132 The parasympathetic cholinergenic salivary innervation of the parotid gland arises in the inferior salivary nucleus, passes through the tympanic plexus via the tympanic nerve (a branch of the glossopharyngeal nerve), through the ramus communicans or lesser petrosal nerve (a branch of the facial nerve), and through the otic ganglion to the auriculotemporal nerve, a branch of the mandibular nerve, which then forms an anastomosis with the extracranial portion of the facial nerve to terminate in the parotid gland. Postparotidectomy gustatory sweating is thought to occur by misdirected regeneration of these parasympathetic nerve fibres, leading to innervation of the sudoral eccrine and vasomotor endplates in the adjacent skin, with gustatory-induced perspiration and vasodilatation in the parotid re,' oion.
Gustatory sweating secondary to parotidectomy may objectively occur in up to 100 per cent of cases, but seems to be subjectively perceived in only about 50 per cent of patients, and subjectively severe enough to warrant treatment in only 6-15 per cent of cases.3 Gustatory sweating can also be caused by diabetes or sympathectomy, and in other cases constitutes an idiopathic, focal hyperhydrosis. The use of forceps has been incriminated as a cause in infants, possibly via trauma to the parotid region.4
Botulinum toxin acts by irreversibly blocking acetylcholine receptors, and was initially developed for military purposes in the 1970s.~ The protein cleaves SNARE (soluble N-ethylrnaleimide-sensitive factor attachment protein receptor) proteins, and has the ultimate effect of inhibiting the exocytosis of acetylcholine by inhibiting the fusion of the neurotransmitter-containing vesicles with the presynaptic cell membrane. Seven different serotypes of botulinum toxin have been described, five of which
